Corinne Epperly M.D. M.P.H. COO 
Caravan Biologix

Dr. Corinne Epperly brings over 20 years of experience in immuno-oncology, clinical development, and biotechnology operations to her current roles in the cell therapy industry. As a physician-scientist turned biotech executive, she combines deep medical expertise with proven business acumen to advance innovative cancer therapies from development through commercialization.

​

Most recently, as Chief Operating Officer at CARGO Therapeutics, Dr. Epperly led the company's efforts in developing next-generation CAR-T cell therapies focused on overcoming resistance mechanisms in cancer treatment. Prior to this, she served as Senior Vice President of Strategy and Operations at Iovance Biotherapeutics, where she played a crucial role in expanding the company's late-stage clinical programs, optimizing cell therapy operations, and preparing for commercial launch.

​

Throughout her career, Dr. Epperly has demonstrated exceptional leadership in both clinical development and commercial strategy. As Chief Operating Officer at VBL Therapeutics, she drove clinical development and commercial planning initiatives that delivered significant financial results. During her tenure at Bristol-Myers Squibb, she served in multiple strategic roles, including Launch Lead for Opdivo across several indications and US Immuno-Oncology Safety Management Lead for both Opdivo and Yervoy. Her experience in global mergers and acquisitions at BMS included leading multibillion-dollar transactions and strategic partnerships.

​

Dr. Epperly's unique background includes experience in financial markets, having served in Healthcare Equity Research at Goldman Sachs, as well as clinical practice as a pediatric resident at the University of North Carolina Hospitals. Her early career included valuable research experience as a Biomedical Research Fellow at the National Cancer Institute (NIH).

​

Currently, Dr. Epperly serves on the boards of several innovative biotech companies, including IN8bio and Sastra Cell Therapy, where she continues to shape the future of cell therapy and immuno-oncology. She is also co-founder and CEO of a stealth-mode company, further demonstrating her ongoing commitment to advancing breakthrough therapies in oncology.

​

Her combination of medical expertise, business acumen, and operational excellence continues to drive innovation in the development and commercialization of novel cancer therapies, particularly in the rapidly evolving field of cell therapy.